Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Starts Presentation at The LD 500
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Citius is focused on the development and commercialization of important new drug products for growing markets. The company is currently advancing three proprietary product candidates: Mino-Lok(R), CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Citius believes the markets for its products are large and underserved by the current standard of care. For more information, visit the company's website at www.citiuspharma.com About The LD 500 The LD 500 is the most ambitious project in…







